198 related articles for article (PubMed ID: 27810689)
1. Efficacy and safety of teneligliptin in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring.
Yajima T; Yajima K; Hayashi M; Takahashi H; Yasuda K
Diabetes Res Clin Pract; 2016 Dec; 122():78-83. PubMed ID: 27810689
[TBL] [Abstract][Full Text] [Related]
2. Improved glycemic control with teneligliptin in patients with type 2 diabetes mellitus on hemodialysis: Evaluation by continuous glucose monitoring.
Wada N; Mori K; Nakagawa C; Sawa J; Kumeda Y; Shoji T; Emoto M; Inaba M
J Diabetes Complications; 2015; 29(8):1310-3. PubMed ID: 26298521
[TBL] [Abstract][Full Text] [Related]
3. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
[TBL] [Abstract][Full Text] [Related]
4. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
Tanaka S; Suzuki K; Aoki C; Niitani M; Kato K; Tomotsune T; Aso Y
Diabetes Technol Ther; 2014 Dec; 16(12):840-5. PubMed ID: 25144424
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
Kadowaki T; Haneda M; Ito H; Sasaki K; Yamada Y
Adv Ther; 2020 May; 37(5):2477-2492. PubMed ID: 32323194
[TBL] [Abstract][Full Text] [Related]
6. Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T).
Takamiya Y; Okamura K; Shirai K; Okuda T; Kobayashi K; Urata H
Clin Exp Hypertens; 2020; 42(3):197-204. PubMed ID: 30974980
[No Abstract] [Full Text] [Related]
7. Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan.
Kadowaki T; Haneda M; Ito H; Sasaki K; Matsukawa M; Yamada Y
Adv Ther; 2020 Mar; 37(3):1065-1086. PubMed ID: 31873865
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes.
Otsuki H; Kosaka T; Nakamura K; Shimomura F; Kuwahara Y; Tsukamoto T
Int Urol Nephrol; 2014 Feb; 46(2):427-32. PubMed ID: 24014134
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial.
Hong S; Park CY; Han KA; Chung CH; Ku BJ; Jang HC; Ahn CW; Lee MK; Moon MK; Son HS; Lee CB; Cho YW; Park SW
Diabetes Obes Metab; 2016 May; 18(5):528-32. PubMed ID: 26749529
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Kadowaki T; Kondo K
Diabetes Obes Metab; 2013 Sep; 15(9):810-8. PubMed ID: 23464664
[TBL] [Abstract][Full Text] [Related]
11. The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.
Ceriello A; De Nigris V; Iijima H; Matsui T; Gouda M
Drugs; 2019 May; 79(7):733-750. PubMed ID: 30982160
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic insights from sequential combination therapy with a sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase-4 inhibitor: Results from the CANARIS Trial using canagliflozin and teneligliptin.
Okahata S; Sakamoto K; Mitsumatsu T; Kondo Y; Tanaka S; Shiba T
Diabetes Obes Metab; 2019 Feb; 21(2):388-392. PubMed ID: 30146790
[TBL] [Abstract][Full Text] [Related]
13. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial.
Eto T; Inoue S; Kadowaki T
Diabetes Obes Metab; 2012 Nov; 14(11):1040-6. PubMed ID: 22776014
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period.
Kadowaki T; Kondo K; Sasaki N; Miyayama K; Yokota S; Terata R; Gouda M
Expert Opin Pharmacother; 2017 Sep; 18(13):1291-1300. PubMed ID: 28741385
[TBL] [Abstract][Full Text] [Related]
15. Teneligliptin for the treatment of type 2 diabetes.
Goda M; Kadowaki T
Drugs Today (Barc); 2013 Oct; 49(10):615-29. PubMed ID: 24191255
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the administration of teneligliptin every day versus every other day in Japanese patients with type 2 diabetes: a randomized non-inferior test.
Kamiko K; Aoki K; Kamiyama H; Taguri M; Shibata E; Ashiya Y; Minagawa F; Shinoda K; Nakajima S; Terauchi Y
J Clin Pharmacol; 2015 Feb; 55(2):144-51. PubMed ID: 25159300
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Effects of Teneligliptin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus.
Kurozumi A; Okada Y; Sugai K; Torimoto K; Tanaka Y
J UOEH; 2018; 40(1):1-9. PubMed ID: 29553070
[TBL] [Abstract][Full Text] [Related]
18. Improved glycemic control with once-weekly dulaglutide in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring.
Yajima T; Yajima K; Hayashi M; Takahashi H; Yasuda K
J Diabetes Complications; 2018 Mar; 32(3):310-315. PubMed ID: 29366733
[TBL] [Abstract][Full Text] [Related]
19. A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis.
Homma K; Yoshizawa J; Shiina Y; Ozawa H; Igarashi M; Matsuoka T; Sasaki J; Yoshizawa M; Homma Y
Drugs R D; 2017 Sep; 17(3):397-402. PubMed ID: 28577292
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Watanabe Y; Gouda M; Iijima H
Diabetes Obes Metab; 2018 Jan; 20(1):77-84. PubMed ID: 28608617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
